



PAO GROUP, INC. Introducing Price Target for Emerging CBD Pharma

Rob Goldman
rob@goldmanresearch.com

September 8, 2020

PAO GROUP, INC. (OTC – PAOG - \$0.0036)	
Industry: CBD Pharma	12 Mo. Price Target: \$0.015

COMPANY SNAPSHOT

PAO Group, Inc. is an emerging cannabis and CBD company targeting growth via two tracks. The Company is in the early stages of developing a cannabis extract-based therapy to treat various respiratory diseases and illnesses including COPD and COVID-19. PAOG also owns a growing cannabis cultivation operation focused on hemp cultivation.

KEY STATISTICS

Price as of 9/4/20	\$0.0036
52 Week High – Low	\$0.0059- \$0.0003
Est. Shares Outstanding	1.28B
Market Capitalization	\$4.6M
Average Volume	67,755,588
Exchange	OTCPK

COMPANY INFORMATION

PAO Group, Inc.
 1190 Cleveland Road
 Suite B
 Sandusky OH 44870

Web: www.Paogroupinc.com
 Email: info@pao.group
 Phone : 888.272.6472

INVESTMENT HIGHLIGHTS

Conclusion: PAO Group currently trades above its 50-day and 200 day moving averages. This bullish status, along with its recently updated financials reporting, should prompt the shares to reach new levels. Moreover, a review of the financials lends us greater confidence in the Company’s R&D financing capabilities and the achievement of key milestones. Thus, we have now introduced a 12-month target of \$0.015, a nearly 5x return from current levels.

Future Developments: This emerging CBD Pharma company is set to evolve from a promising preclinical firm toward a Phase I development path entity. PAOG has multiple shots on goal as it seeks to treat two major respiratory diseases that each represent billions in potential market sizes.

Next steps include engaging a CRO to initiate the process for potential FDA approval of *RespRx*, its COPD treatment, representing an estimated \$14.1B market by 2025. Plus, PAOG is preparing to commence a similar development pathway for COVID-19 via a CTAP (Coronavirus Treatment Acceleration Program) application. We expect this application to be fast-tracked, given that the use of CBDs to treat these diseases is novel and based on a natural (and likely safer) product.

Price Target/ Higher Valuation: By running concurrent development programs resulting in two IND filings within the next year, we believe that such events could support a \$20M valuation, or a \$0.015 price target. This targeted valuation is in line with IND-filing stocks. Moreover, with no long term debt on the books, PAOG has significant funding flexibility to continue on its R&D paths.

RECENT TRADING HISTORY FOR PAO GROUP INC.

(Source: www.StockCharts.com)





SENIOR ANALYST: ROBERT GOLDMAN

Rob Goldman founded Goldman Small Cap Research in 2009 and has over 25 years of investment and company research experience as a senior research analyst and as a portfolio and mutual fund manager. During his tenure as a sell side analyst, Rob was a senior member of Piper Jaffray's Technology and Communications teams. Prior to joining Piper, Rob led Josephthal & Co.'s Washington-based Emerging Growth Research Group. In addition to his sell-side experience Rob served as Chief Investment Officer of a boutique investment management firm and Blue and White Investment Management, where he managed Small Cap Growth portfolios and *The Blue and White Fund*.

ANALYST CERTIFICATION

I, Robert Goldman, hereby certify that the view expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research report.

DISCLAIMER

This *Opportunity Research* report was prepared for informational purposes only.

Goldman Small Cap Research, (a division of Two Triangle Consulting Group, LLC) produces research via two formats: *Goldman Select Research* and *Goldman Opportunity Research*. The *Select* format reflects the Firm's internally generated stock ideas along with economic and stock market outlooks. *Opportunity Research* reports, updates and Microcap Hot Topics articles reflect sponsored (paid) research but can also include non-sponsored micro-cap research ideas that typically carry greater risks than those stocks covered in the *Select Research* category. It is important to note that while we may track performance separately, we utilize many of the same coverage criteria in determining coverage of all stocks in both research formats. Research reports on profiled stocks in the *Opportunity Research* format typically have a higher risk profile and may offer greater upside. *Goldman Small Cap Research* was compensated the Company in the amount of \$3500 for research report production and distribution, including a press release. Other companies mentioned in this report, including Puration, Inc. and Kali, Inc have compensated GSCR for research services. Since 2018, Puration has compensated GSCR \$29,000 for research and other due diligence and fairness opinions. During 2019, GSCR was compensated \$7000 by Kali, Inc. for research services. All information contained in this report was provided by the Company via filings, press releases or its website, or through our own due diligence. Our analysts are responsible only to the public, and are paid in advance to eliminate pecuniary interests, retain editorial control, and ensure independence. Analysts are compensated on a per report basis and not on the basis of his/her recommendations.

Goldman Small Cap Research is not affiliated in any way with Goldman Sachs & Co.

Separate from the factual content of our articles about the Company, we may from time to time include our own opinions about the Company, its business, markets and opportunities. Any opinions we may offer about the Company are solely our own and are made in reliance upon our rights under the First Amendment to the U.S. Constitution, and are provided solely for the general opinionated discussion of our readers. Our opinions should not be considered to be complete, precise, accurate, or current investment advice. Such information and the opinions expressed are subject to change without notice.

The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. *Goldman Small Cap Research* did not make an

independent investigation or inquiry as to the accuracy of any information provided by the Company, or other firms. *Goldman Small Cap Research* relied solely upon information provided by the Company through its filings, press releases, presentations, and through its own internal due diligence for accuracy and completeness. Such information and the opinions expressed are subject to change without notice. A *Goldman Small Cap Research* report or note is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. This report does not take into account the investment objectives, financial situation, or particular needs of any particular person. This report does not provide all information material to an investor's decision about whether or not to make any investment. Any discussion of risks in this presentation is not a disclosure of all risks or a complete discussion of the risks mentioned. Neither *Goldman Small Cap Research*, nor its parent, is registered as a securities broker-dealer or an investment adviser with FINRA, the U.S. Securities and Exchange Commission or with any state securities regulatory authority.

ALL INFORMATION IN THIS REPORT IS PROVIDED "AS IS" WITHOUT WARRANTIES, EXPRESSED OR IMPLIED, OR REPRESENTATIONS OF ANY KIND. TO THE FULLEST EXTENT PERMISSIBLE UNDER APPLICABLE LAW, *TWO TRIANGLE CONSULTING GROUP, LLC* WILL NOT BE LIABLE FOR THE QUALITY, ACCURACY, COMPLETENESS, RELIABILITY OR TIMELINESS OF THIS INFORMATION, OR FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL, INCIDENTAL, SPECIAL OR PUNITIVE DAMAGES THAT MAY ARISE OUT OF THE USE OF THIS INFORMATION BY YOU OR ANYONE ELSE (INCLUDING, BUT NOT LIMITED TO, LOST PROFITS, LOSS OF OPPORTUNITIES, TRADING LOSSES, AND DAMAGES THAT MAY RESULT FROM ANY INACCURACY OR INCOMPLETENESS OF THIS INFORMATION). TO THE FULLEST EXTENT PERMITTED BY LAW, *TWO TRIANGLE CONSULTING GROUP, LLC* WILL NOT BE LIABLE TO YOU OR ANYONE ELSE UNDER ANY TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY, PRODUCTS LIABILITY, OR OTHER THEORY WITH RESPECT TO THIS PRESENTATION OF INFORMATION.

For more information, visit our Disclaimer: www.goldmanresearch.com